BioDelivery Sciences sales may jump on DEA move, says Summer Street Summer Street believes the Drug Enforcement Agency's announcement yesterday that it will reschedule all hydrocodone combination products to schedule II from schedule III could allow BioDelivery Sciences's BEMA Buprenorphine to potentially reach significantly higher sales levels. The firm says BEMA Buprenorphine will now have an easier compare against Vicodin and generic equivalents. Summer Street has a Buy rating on BioDelivery with a $20 price target.
On The Fly: After Hours Movers UP AFTER EARNINGS: Progress Software (PRGS), up 6.6%. ALSO HIGHER: Xoom (XOOM), up 22% after announcing company to be acquired by PayPal... BioDelivery Sciences (BDSI), up 4.7% after Point72 Asset Management reports 5.5% passive stake in the company... Green Brick Partners (GRBK), up 7.5% after Third Point reports 16.9% stake in the company.